<!DOCTYPE html><html xmlns="http://www.w3.org/1999/xhtml"><head><title>Ace Exam</title><meta name="generator" content="Hovercraft! 1.0 http://regebro.github.com/hovercraft"></meta><meta name="author" content="Bas Rustenburg"></meta><meta name="description" content="Admission to candidacy exam"></meta><meta name="keywords" content="exam, ace, phd"></meta><link rel="stylesheet" href="css/hovercraft.css" media="all"></link><link rel="stylesheet" href="css/impressConsole.css" media="all"></link><link rel="stylesheet" href="css/highlight.css" media="all"></link><link rel="stylesheet" href="ace.css" media="screen,projection"></link></head><body class="impress-not-supported"><div id="impress" data-transition-duration="1"><div class="step" step="0" id="title" data-x="0" data-y="0"><h1 id="toward-addressing-deficiencies-in-alchemical-free-energy-calculations">Toward addressing deficiencies in alchemical free energy calculations</h1><h2 id="bas-rustenburg">Bas Rustenburg</h2><h3 id="date-5-29">Date : 5/29</h3><img src="images/background.png" alt="" width="90%" height=""></img></div><div class="step" step="1" data-x="1600" data-y="0"><h1 id="the-efficiency-of-the-pharmaceutical-industry-has-been-declining-for-years">The efficiency of the pharmaceutical industry has been declining for years</h1><img src="images/erooms.jpg" alt="" width="90%" height=""></img>Kack W. Scannell et al. <em>Nature Reviews Drug Discovery</em> 11, 191-200 (2012)</div><div class="step" step="2" data-x="3200" data-y="0"><h1 id="it-takes-up-to-4-5-years-and-219-million-dollars-to-develop-a-potent-binder">It takes up to 4.5 years and 219 million dollars to develop a potent binder</h1><img src="images/drug_disc_cost.png" alt="" width="90%" height=""></img>Paul, SM, et al. <em>Nature Reviews Drug Discovery</em> 9, 203-214 (2010)<p>Each consecutive step only gets more expensive!</p></div><div class="step" step="3" data-x="4800" data-y="0"><h1 id="there-is-a-clear-need-for-a-cheaper-strategy">There is a clear need for a cheaper strategy</h1><h2 id="computational-approaches-offer-a-cheap-solution">Computational approaches offer a cheap solution</h2><ul><li>They benefit from Moore's law, with <em>increased computational efficiency each year</em></li><li>Ability to study <em>hypothetical small molecules</em></li><li>Allow for <em>faster</em> and <em>cheaper</em> generation of drug candidates<ul><li>More leads to follow in the later stage, reducing failure rate.</li></ul></li></ul><div class="notes"><p>Give us more chances to hit our target.</p><p>Maybe some leads will be toxic, of have ADME issues</p><p>For instance,
* compounds that have not been synthesized.
* when protein is expensive.
* When you cant reach concentrations of poorly soluble drugs.</p></div></div><div class="step" step="4" data-x="6400" data-y="0"><h1 id="it-is-all-about-the-binding-affinity">It is all about the binding affinity</h1><p>A strong binder minimizes the ratio of free protein (<strong>[P]</strong>) and ligand (<strong>[L]</strong>) over complex concentration (<strong>[PL]</strong>).</p><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/colored_PL.png" alt="" width="70%" height=""></img></td></tr></tbody></table><p>This is known as the dissociation constant (<strong>Kd</strong>), often used synonymously with the binding affinity.</p><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/colored_kdkoff.png" alt="" width="70%" height=""></img></td></tr></tbody></table><p>This can be related to the free energy of binding, <strong>&#x394;G</strong>.</p><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/colored_Kd.png" alt="" width="60%" height=""></img></td></tr></tbody></table></div><div class="step" step="5" id="docking" data-x="8000" data-y="0"><h1 id="molecular-docking-for-affinity-estimation">Molecular docking for affinity estimation</h1><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/docking.gif" alt="" width="90%" height=""></img>Molecule is docked into a rigid receptor</td><td><img src="images/scoring.jpg" alt="" width="90%" height=""></img>Free energy is estimated by a scoring function.</td></tr></tbody></table></div><div class="step" step="6" data-x="9600" data-y="0"><h1 id="docking-scores-do-not-correlate-with-affinity">Docking scores do not correlate with affinity</h1><p><em>For prediction of compound affinity, none of the docking programs or scoring functions made
a useful prediction of ligand binding affinity.</em></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/docking.png" alt="" width="60%" height=""></img></td></tr></tbody></table><p>At most, the top 10-20% cores shows an <a href="index.html#/enrichment">enrichment</a> in binders.</p><blockquote><p>Warren et al. <em>J Med Chem</em> 49 (20), pp 5912&#x2013;5931 (2006)</p></blockquote></div><div class="step" step="7" id="deshaw" data-x="11200" data-y="0"><h1 id="if-you-have-a-fast-super-computer">If you have a fast super-computer</h1><p>You can observe binding in <em>microsecond timescale</em> MD simulations.</p><img src="images/deshaw2.gif" alt="" width="" height=""></img><p>For typical drug off-rates, trajectories would need to be impractically long (hours), requiring ~100 million CPU-years to simulate.</p><div class="notes"><dl><dt>imatinib to abl:</dt><dd><ul><li>kon 0.146 uM s-1</li><li>koff 0.0022 s-1 (1/500s)</li></ul><p>Say we need 100 events. 50 000 seconds needed
(50 000 seconds) / (100 (nanoseconds / gpu days)) =
1.36895463 billion gpu years</p></dd></dl></div></div><div class="step" step="8" data-x="12800" data-y="0"><h1 id="alchemical-free-energy-calculations">Alchemical free energy calculations</h1><h2 id="in-principle-allow-for-us-to-calculate-affinities-indirectly">(in principle) allow for us to calculate affinities indirectly.</h2><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/colored_Kd.png" alt="" width="60%" height=""></img></td></tr><tr><td><a href="index.html#/alchem-intermediates"><img src="images/alchemical_intermediates.png" alt="" width="80%" height=""></img></a></td></tr></tbody></table><p>Chodera, JD et al. <em>Curr Opin Struct Biol</em>, 21:150 (2011)</p></div><div class="step" step="9" data-x="14400" data-y="0"><h1 id="successful-applications">Successful applications</h1><p>Schrodinger has shown that their free energy calculation framework can calculate binding free energies that are:</p><blockquote><ul><li>Close to experimental estimates</li><li>Transferrable to several different systems</li></ul></blockquote><img src="images/schrodinger.jpg" alt="" width="50%" height=""></img><p>Wang, L et al. <em>J Am Chem Soc</em> 137 (7), pp 2695&#x2013;2703 (2015)</p></div><div class="step" step="10" data-x="16000" data-y="0"><h1 id="id1">Alchemical free energy calculations</h1><p>There are deficiencies that need to be addressed before alchemical free energy calculations can be applied widely.</p><img src="images/alchem_aims_red.png" alt="" width="95%" height=""></img></div><div class="step" step="11" id="spec-aims" data-x="17600" data-y="0"><h1 id="id2">Alchemical free energy calculations</h1><p>There are deficiencies that need to be addressed before alchemical free energy calculations can be applied widely.</p><img src="images/alchem_aims_mols.png" alt="" width="95%" height=""></img></div><div class="step" step="12" data-x="19200" data-y="0"><h1 id="id3">Alchemical free energy calculations</h1><p>There are deficiencies that need to be addressed before alchemical free energy calculations can be applied widely.</p><img src="images/alchem_aims_red.png" alt="" width="95%" height=""></img><p>We will resolve deficiencies by using a combination of <em>theory</em> and <em>experiments</em>.</p></div><div class="step" step="13" id="aim1" data-x="20800" data-y="0"><h1 id="establish-a-correct-quantitative-treatment-of-alchemical-free-energy-calculations-for-binding-of-charged-ligands">Establish a correct quantitative treatment of alchemical free energy calculations for binding of charged ligands</h1><h2 id="aim-1">Aim 1.</h2><img src="images/alchem_aims_charge.png" alt="" width="95%" height=""></img></div><div class="step" step="14" data-x="22400" data-y="0"><h1 id="disease-relevant-charged-ligands">Disease relevant charged ligands</h1><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/saquinavir.png" alt="" width="50%" height=""></img>Saquinavir</td><td rowspan="2"><img src="images/nelfinavir.png" alt="" width="60%" height=""></img>Nelfinavir</td></tr><tr><td><img src="images/indinavir.png" alt="" width="50%" height=""></img>Indinavir</td></tr></tbody></table><p>Protease inhibitors typically have positive charges. For instance these FDA approved <em>HIV-protease inhibitors</em>.</p><p>(image source: www.chemicalize.org)</p></div><div class="step" step="15" data-x="24000" data-y="0"><h1 id="id4">Disease relevant charged ligands</h1><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/aspirin.png" alt="" width="50%" height=""></img>Aspirin</td><td><img src="images/ibuprofen.png" alt="" width="50%" height=""></img><p>Ibuprofen</p></td></tr></tbody></table><p>Many over-the-counter <em>nonsteroidal anti-inflammatory drugs</em> have charged moieties!</p><p>(image source: www.chemicalize.org)</p></div><div class="step" step="16" data-x="25600" data-y="0"><h1 id="id5">Disease relevant charged ligands</h1><h2 id="anti-histamines">Anti-histamines</h2><table cellpadding="0" cellspacing="0"><tbody><tr><td rowspan="2"><img src="images/histamine.png" alt="" width="70%" height=""></img>Histamine</td><td><img src="images/diphenhydramine.png" alt="" width="40%" height=""></img>Benadryl (diphenhydramine)</td></tr><tr><td><img src="images/azelastine.png" alt="" width="40%" height=""></img>Astelin (azelastine)</td></tr></tbody></table><p>(image source: www.chemicalize.org)</p></div><div class="step" step="17" data-x="27200" data-y="0"><h1 id="why-are-there-issues-with-in-charged-ligands">Why are there issues with in charged ligands?</h1><p>Bulk liquids are huge, therefore, a number of <a href="index.html#/approximations">approximations</a> are made:</p><ul><li>Periodic boundary conditions, or implicit solvents</li><li>Truncating electrostatic potentials (cut-offs)</li><li>Non-coulombic long-range electrostatics<ul><li>Ewald <a href="index.html#/ewald">summation</a> (or particle mesh Ewald, PME)</li><li>Reaction field models (RF)</li></ul></li></ul><img src="images/reif_oostenbrink.png" alt="" width="" height=""></img><p>Reif, MM  and Oostenbrink, C  <em>J Comput Chem</em>  35.3  pp. 227&#x2013;243 (2013)</p></div><div class="step" step="18" data-x="28800" data-y="0"><h1 id="what-can-be-done-to-resolve-the-issues">What can be done to resolve the issues?</h1><dl><dt>A number of <a href="index.html#/rocklin">corrections</a> have been proposed but:</dt><dd><ul><li>They have not been compared to each other<ul><li>Not used on the same systems</li></ul></li><li>Quantitative correctness of these methods has not been established<ul><li>Not compared to experiment!</li></ul></li></ul></dd><dt>Sources:</dt><dd><ul><li>Reif MM and Oostenbrink C <em>J Comput Chem</em> 35.3 , pp. 227&#x2013;243 (2013)</li><li>Rocklin GJ et al. <em>J Chem Phys</em> 139.18 , p. 184103. (2013)</li><li>Lin YL et al. <em>J Chem Theory Comput</em> 10.7, pp. 2690&#x2013;2709. (2014)</li></ul></dd></dl></div><div class="step" step="19" data-x="30400" data-y="0"><h1 id="compare-the-different-charge-correction-models">Compare the different charge correction models</h1><p>We will consider these approaches:</p><ul><li>Reif and Oostenbrink use thermodynamic cycles to eliminate individual components.</li><li>Rocklin et al. use Poisson-Boltzmann calculations to quantify the erroneous contributions.</li><li>Lin et al. use potential of mean force (PMF) calculations in a large simulation system, pulling the ligand away from the protein non-alchemically.</li><li>Eliminating a pair of ions, with a net charge of <strong>0</strong>.</li></ul><ol><li>We will check if the methods produce the <em>same quantitative estimate</em>.</li><li>We will compare to experiment, to see if they produce a <em>quantitatively correct answer</em>.</li></ol><p>This is the first comparison of any of these methods on the same system!</p></div><div class="step" step="20" id="approximations" data-x="32000" data-y="0"><h1 id="issues-arrising-from-using-ewald-summation">Issues arrising from using Ewald summation</h1><h2 id="neutralizing-the-system-charge">Neutralizing the system charge</h2><p>There is an effective system neutralizing charge, called jellium/gellium.</p><p>This system wide charge density <strong>&#x3C1;</strong> depends on the box size, <strong>L</strong>.</p><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/box_sizes.png" alt="" width="50%" height=""></img>The charge density differs between complex and ligand
because of a net charge change and the box size.</td><td><img src="images/colored_gellium.png" alt="" width="90%" height=""></img>The charge density in the system is a function of the box size.</td></tr></tbody></table><p>Lin YL et al. <em>J Chem Theory Comput</em> 10.7, pp. 2690&#x2013;2709. (2014)</p></div><div class="step" step="21" data-x="33600" data-y="0"><h1 id="what-system-will-we-use-to-test">What system will we use to test?</h1><h2 id="cucurbit-7-uril-as-a-model-system">Cucurbit-[7]-uril as a model system</h2><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/guest11_top.png" alt="" width="50%" height=""></img></td><td><img src="images/guest11_side.png" alt="" width="50%" height=""></img></td></tr></tbody></table><div class="notes"><p><em>It binds cationic guests</em></p><p>resembles protein backbone</p></div></div><div class="step" step="22" data-x="35200" data-y="0"><h1 id="hosts-are-the-active-component-in-febreze">Hosts are the active component in Febreze!</h1><img src="images/febreze.jpg" alt="" width="" height=""></img></div><div class="step" step="23" data-x="36800" data-y="0"><h1 id="id6">Cucurbit-[7]-uril as a model system</h1><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/guest11_top.png" alt="" width="70%" height=""></img></td><td><img src="images/guest11_side.png" alt="" width="70%" height=""></img></td><td rowspan="2"><p>The system is useful because:</p><ul><li>Both guest and hosts are very soluble</li><li>They are small, with few degrees of freedom</li><li>The affinities are in the range of typical protein-small molecule interactions</li></ul></td></tr><tr><td colspan="2"><img src="images/Kd_guest2.png" alt="" width="80%" height=""></img></td></tr></tbody></table></div><div class="step" step="24" data-x="38400" data-y="0"><h1 id="experimental-validation">Experimental validation</h1><p>In order to <em>quantitatively validate the free energy correction methods</em>, we will be performing experiments to measure the free energy of binding.</p><ul><li>We will perform <em>isothermal titration calorimetry</em> (ITC) experiments that can validate the different corrections.</li><li>ITC experiments are very compatible with free energy calculations because you <em>directly measure thermodynamic characteristics</em> of binding<ul><li>The <em>free energy</em>, and <em>enthalpy</em></li></ul></li></ul></div><div class="step" step="25" data-x="40000" data-y="0"><h1 id="itc-experiments">ITC experiments</h1><p>Host-guest data have a high signal to noise because of the solubility, making it excellent for a quantitative test of our approach.</p><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/itcexp.png" alt="" width="90%" height=""></img></td><td><img src="images/itcinstrument.jpg" alt="" width="90%" height=""></img></td></tr></tbody></table><p>Zhou et al. <em>Nature Protocols</em> 6, 158&#x2013;165 (2011)</p></div><div class="step" step="26" data-x="41600" data-y="0"><h1 id="isothermal-titration-calorimety">Isothermal titration calorimety</h1><h2 id="parameters-are-fit-to-the-integrated-peaks">Parameters are fit to the integrated peaks</h2><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/itcexample.jpg" alt="" width="90%" height=""></img></td></tr></tbody></table><p><a href="http://www.biochemistry.ucla.edu/biochem/shared/instruments/Isothermal.html">http://www.biochemistry.ucla.edu/biochem/shared/instruments/Isothermal.html</a></p><div class="notes"><p>The heats are fit to the equation</p><p>Qi = V * n * H * [PL]
deltaQ is heat per injection</p></div></div><div class="step" step="27" data-x="43200" data-y="0"><h1 id="isothermal-titration-calorimetry">Isothermal titration calorimetry</h1><h2 id="there-are-some-issues-with-the-standard-analysis">There are some issues with the standard analysis...</h2></div><div class="step" step="28" data-x="44800" data-y="0"><h1 id="binding-of-cbs-to-bovine-carbonic-anhydrase-ii">Binding of CBS to bovine carbonic anhydrase II</h1><h2 id="observations-from-the-abrf-mirg-02-study">Observations from the ABRF-MIRG'02 study</h2><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/abrf_mirg.png" alt="" width="70%" height=""></img></td><td><img src="images/itcexample_r.jpg" alt="" width="110%" height=""></img></td></tr></tbody></table><p>Myszka DG et al. <em>J Biomol Tech</em> 2003 Dec; 14(4):247-69</p><div class="notes"><p>Association of Biomolecular Resource Facilities</p><p>CBS stands for 4-carboxybenzenesulfonamide</p></div></div><div class="step" step="29" data-x="46400" data-y="0"><h1 id="observed-errors-can-directly-be-correlated-to-errors-in-concentration">Observed errors can directly be correlated to errors in concentration</h1><p>The extinction coefficient</p><img src="images/extinction_mirg.png" alt="" width="40%" height=""></img><dl><dt>From the Lambert-Beer law:</dt><dd><img src="images/colored_extinction.png" alt="" width="30%" height=""></img></dd></dl><p>where A is absorbance, c is concentration and l is the pathlength</p></div><div class="step" step="30" data-x="48000" data-y="0"><h1 id="why-still-use-itc">Why still use ITC?</h1><ul><li>No approximations/assumptions needed to access <em>thermodynamic properties</em> of a binding reaction<blockquote><ul><li>Therefore, they can be directly related to alchemical free energy calculations!</li></ul></blockquote></li><li>There is no need for fluorescent scaffolds or tags</li><li>There HAS to be a way to quantify the uncertainty accurately<ul><li>We suggest using <em>Bayesian inference</em>.</li></ul></li></ul></div><div class="step" step="31" data-x="49600" data-y="0"><h1 id="accurately-quantify-experimental-uncertainty-using-bayesian-inference">Accurately quantify experimental uncertainty using Bayesian inference.</h1><p>The experimental <a href="index.html#/parameters">parameters</a>, &#x3B8;</p><img src="images/colored_parameters.png" alt="" width="50%" height=""></img><p>can be estimated using Bayes rule:</p><img src="images/colored_bayes_rule.png" alt="" width="30%" height=""></img><ul><li><strong>P(&#x3B8;|D)</strong> is the <em>posterior</em> distribution. The probability of the parameters given the observed data. <em>This is what we want to know!</em></li><li><strong>P(D|&#x3B8;)</strong> is the <em>likelihood</em>. The probability of the observed data, given a single set of parameters.</li><li><strong>P(&#x3B8;)</strong> are <em>prior</em> distributions, containing prior information. We can use this to propagate errors such as known errors in reagent concentrations.</li></ul></div><div class="step" step="32" data-x="51200" data-y="0"><h1 id="likelihood-model-of-the-data">Likelihood model of the data</h1><p>We assume the injection heats, q_n are drawn from a normal distribution, with the true heats as a mean, and a variance <strong>&#x3C3;</strong>.</p><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/colored_model.png" alt="" width="40%" height=""></img></td></tr><tr><td><img src="images/colored_qn_itc.png" alt="" width="50%" height=""></img></td></tr><tr><td><img src="images/itc_test2.png" alt="" width="60%" height=""></img></td></tr></tbody></table></div><div class="step" step="33" data-x="52800" data-y="0"><h1 id="id7">Accurately quantify experimental uncertainty using Bayesian inference.</h1><p>Our posterior then becomes</p><img src="images/hl_full_bayes.png" alt="" width="60%" height=""></img><p>and to estimate the posterior, we can sample from it using techniques like <em>Markov Chain Monte Carlo</em> (MCMC).</p></div><div class="step" step="34" data-x="54400" data-y="0"><h1 id="sampling-from-a-posterior-distribution-using-mcmc">Sampling from a posterior distribution using MCMC</h1><a href="index.html#/postheats"><img src="images/posteriors.png" alt="" width="70%" height=""></img></a></div><div class="step" step="35" data-x="56000" data-y="0"><h1 id="marginalize-out-other-parameters-to-obtain-uncertainties">Marginalize out other parameters to obtain uncertainties</h1><img src="images/marginals.png" alt="" width="60%" height=""></img></div><div class="step" step="36" data-x="57600" data-y="0"><h1 id="making-our-tools-accessible-as-a-library">Making our tools accessible as a library</h1><h2 id="the-code-is-already-available-on-github">The code is already available on github</h2><img src="images/github.png" alt="" width="70%" height=""></img><p><a href="https://github.com/choderalab/bayesian-itc">https://github.com/choderalab/bayesian-itc</a></p></div><div class="step" step="37" data-x="59200" data-y="0"><h1 id="id8">Establish a correct quantitative treatment of alchemical free energy calculations for binding of charged ligands</h1><p>Using the <em>Cucurbit[7]uril host-guest system</em>, we will</p><p><em>1.1.</em> Develop an accurate approach to quantifying experimental uncertainty in ITC using Bayesian inference.</p><p><em>1.2.</em> Perform a quantitative comparison of suggested correction models to experiment to establish a correct treatment of charged ligands in alchemical free energy calculations.</p></div><div class="step" step="38" id="aim2" data-x="60800" data-y="0"><h1 id="quantify-the-magnitude-of-protonation-state-effects-on-binding">Quantify the magnitude of protonation state effects on binding</h1><h2 id="aim-2">Aim 2.</h2><img src="images/alchem_aims_protonation.png" alt="" width="70%" height=""></img></div><div class="step" step="39" data-x="62400" data-y="0"><h1 id="id9">Quantify the magnitude of protonation state effects on binding</h1><p>We do not know every relevant protonation state a priori, and how relevant they are to the binding affinity.</p><img src="images/protonation.png" alt="" width="80%" height=""></img><em>The pH dependent effect in lin-benzoguanines binding to tRNA&#x2212;guanine transglycosylase</em><p>Neeb et al. <em>J. Med. Chem.</em>, 2014, 57 (13), pp 5554&#x2013;5565</p><div class="notes"><p>Also known for proteases and... kinases.</p></div></div><div class="step" step="40" data-x="64000" data-y="0"><h1 id="problems-with-the-standard-approach">Problems with the standard approach</h1><ol><li>If we observe significant mixtures of protonation states</li><li>The distribution of protonation states change significantly upon binding</li></ol><p>Then the standard approach is <strong>missing contributions of unknown magnitude</strong>.</p><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/histidine.png" alt="" width="90%" height=""></img></td><td><img src="images/lapatinib.png" alt="" width="50%" height=""></img></td></tr></tbody></table><p>Our aim is to <em>extend our free energy calculation framework</em> to include dynamical protonation states, to accurately account for them in simulation.</p></div><div class="step" step="41" data-x="65600" data-y="0"><h1 id="protonation-states-may-vary-for-kinase-inhibitors">Protonation states may vary for kinase inhibitors</h1><h2 id="imatinib-a-potent-inhibitor-of-abl-kinase">Imatinib, a potent inhibitor of Abl kinase</h2><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/imatinib_sites.png" alt="" width="35%" height=""></img></td></tr><tr><td><img src="images/ima_cycle.png" alt="" width="50%" height=""></img></td></tr></tbody></table><p>Aleksandrov, A and Simonson, T <em>J Comput Chem</em> 31,7, pp. 1550&#x2013;1560 (2010)</p></div><div class="step" step="42" data-x="67200" data-y="0"><h1 id="protonation-states-are-relevant-to-kinase-inhibitors">Protonation states are relevant to kinase inhibitors</h1><ul><li>Preliminary data indicates that it is the same for <em>many other kinase inhibitors</em>.</li></ul><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/inhibitor-pKas.png" alt="" width="80%" height=""></img></td></tr></tbody></table><p>Preliminary data generated using Epik</p><p>Shelley, JC <em>J Comput -Aided Mol Des</em> 21, pp. 681&#x2013;691 (2007)</p></div><div class="step" step="43" data-x="68800" data-y="0"><h1 id="survey-the-kinase-inhibitor-cocrystal-structures-for-possible-protonation-state-effects-in-inhibitor-binding">Survey the kinase:inhibitor cocrystal structures for possible protonation state effects in inhibitor binding.</h1><h2 id="perform-a-survey-accross-all-human-kinase-complexes-in-the-protein-databank-pdb">Perform a survey accross all (human) kinase complexes in the protein databank (PDB)</h2><img src="images/imatinib_sites.png" alt="" width="60%" height=""></img></div><div class="step" step="44" data-x="70400" data-y="0"><h1 id="our-aim-is-to-identify-kinase-systems-where-protonation-state-effects-influence-binding">Our aim is to identify kinase systems where protonation state effects influence binding</h1><h2 id="to-quantify-the-effect-of-protonation-state-effects-on-the-binding-affinity-of-kinase-inhibitors">to quantify the effect of protonation state effects on the binding affinity of kinase inhibitors.</h2><ul><li>There are 3500+ kinase:inhibitor complex structures in the protein databank.</li><li>Using a simple tool, we want to survey them to narrow down to a set of max 100 complexes that show changes in the protonation state.</li></ul><p>Once identified we will</p><ul><li>Use alchemical free energy calculations, extended to sample protonation states to <em>quantify the contribution</em></li><li>Perform ITC experiments to validate them.</li></ul></div><div class="step" step="45" data-x="72000" data-y="0"><h1 id="multi-conformation-continuum-electrostatic-mcce">Multi-conformation continuum electrostatic (MCCE)</h1><ul><li>MCCE samples multiple conformations of protein side-chains</li><li>It allows for random changes to the protonation state using Monte Carlo</li></ul><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/dGprotonation.png" alt="" width="45%" height=""></img></td></tr><tr><td><img src="images/mcce2_sharp.png" alt="" width="40%" height=""></img></td></tr></tbody></table><p>Song, Y et al. <em>J Comput Chem</em> 30: 2231&#x2013;2247 (2009)</p><div class="notes"><p>G elec is the electrostatic component of the free energy calculated for the titratable group in the protein,</p><p>G elec,ref is the electrostatic component of the transition free energy for the reference compound</p><p>Ref is peptide in solution</p></div></div><div class="step" step="46" data-x="73600" data-y="0"><h1 id="id10">Multi-conformation continuum electrostatic (MCCE)</h1><ul><li>We will extend the framework to incorporate sampling of ligands protonation states.</li></ul><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/dGprotonation2.png" alt="" width="500px" height=""></img></td></tr></tbody></table><ul><li>Reference values are only available for amino acids</li><li>We need pKa estimates for ALL the kinase inhibitors studied!</li></ul></div><div class="step" step="47" data-x="75200" data-y="0"><h1 id="we-will-benchmark-small-molecule-pka-prediction-tools-against-experimental-data-data">We will benchmark small molecule pKa prediction tools against experimental data data.</h1><ul><li>There is pKa data available for a number of kinase inhibitors that are FDA approved.</li><li>Using this data, we will benchmark available pKa prediction tools.</li></ul><p>Szak&#xE1;cs Z, et al. <em>J Med Chem</em> 48, 249&#x2013;255 (2005)</p></div><div class="step" step="48" data-x="76800" data-y="0"><h1 id="there-are-a-lot-of-rough-approximations-in-mcce">There are a lot of rough approximations in MCCE</h1><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/mcce2_sharp.png" alt="" width="400px" height=""></img></td></tr></tbody></table><ul><li>No dynamics included of the protein backbone</li><li>A single ligand orientation (crystal structure)</li></ul><p>Therefore we can only use it to survey and not to quantify.</p></div><div class="step" step="49" data-x="78400" data-y="0"><h1 id="we-will-use-alchemical-free-energy-calculations-to-quantify">We will use alchemical free energy calculations to quantify</h1><blockquote><ul><li>The total free energy of binding</li><li>The contribution of protonation state changes to the total.</li><li>We will implement a Monte Carlo titration scheme</li></ul><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/acceptance_ph.png" alt="" width="50%" height=""></img></td></tr></tbody></table></blockquote></div><div class="step" step="50" data-x="80000" data-y="0"><h1 id="itc-experiments-to-disseminate-protonation-state-effects-from-binding">ITC experiments to disseminate protonation state effects from binding</h1><ul><li>We can use <em>multiple experiments in different buffers</em> to detect protonation state effects in ITC</li><li>Because of different <em>ionization enthalpies</em>, if a proton is exchanged with the buffer, there will be a different enthalpy of binding.</li></ul><img src="images/buffer_dependency.gif" alt="" width="50%" height=""></img><p>Neeb et al. <em>J. Med. Chem.</em>, 2014, 57 (13), pp 5554&#x2013;5565</p></div><div class="step" step="51" data-x="81600" data-y="0"><h1 id="id11">Quantify the magnitude of protonation state effects on binding</h1><p>We will identify kinase-inhibitor systems that show changes in the populations of protonation states from MCCE calculations.</p><p><em>2.1</em> Benchmark small molecule pKa prediction tools against experimental data for kinase inhibitors.</p><p><em>2.2</em> Survey the kinase:inhibitor cocrystal structures for possible protonation state effects in inhibitor binding.</p><p><em>2.3</em> Dissect the determinants and impact of protonation state effects on binding affinity through free energy calculations and ITC experiments.</p></div><div class="step" step="52" data-x="83200" data-y="0"><h1 id="id12">Alchemical free energy calculations</h1><p>There are deficiencies that need to be addressed before alchemical free energy calculations can be applied widely.</p><img src="images/alchem_aims_multi.png" alt="" width="95%" height=""></img></div><div class="step" step="53" data-x="84800" data-y="0"><h1 id="binding-of-multiple-ligands-to-human-serum-albumin">Binding of multiple ligands to human serum albumin</h1><img src="images/HSA.png" alt="" width="55%" height=""></img>A summary of human serum albumin (HSA) crystal structures bound to small molecules.<p>Ghuman, J et al. <em>J Mol Biol</em> 2005, 353, 38&#x2013;52</p></div><div class="step" step="54" data-x="86400" data-y="0"><h1 id="id13">Binding of multiple ligands to human serum albumin</h1><img src="images/HSA_drugsites.png" alt="" width="55%" height=""></img>A summary of human serum albumin (HSA) crystal structures bound to small molecules.<p>Ghuman, J et al. <em>J Mol Biol</em> 2005, 353, 38&#x2013;52</p></div><div class="step" step="55" data-x="88000" data-y="0"><h1 id="id14">Binding of multiple ligands to human serum albumin</h1><img src="images/HSA_extrasites.png" alt="" width="55%" height=""></img>A summary of human serum albumin (HSA) crystal structures bound to small molecules.<p>Ghuman, J et al. <em>J Mol Biol</em> 2005, 353, 38&#x2013;52</p></div><div class="step" step="56" data-x="89600" data-y="0"><h1 id="binding-of-multiple-ligands-to-a-single-target">Binding of multiple ligands to a single target</h1><h2 id="fragment-based-drug-discovery">Fragment based drug discovery</h2><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/hts.jpg" alt="" width="70%" height=""></img>A conventional high-throughput screening hit.</td><td><img src="images/fbdd.jpg" alt="" width="80%" height=""></img>A fragment hit that is later optimized.</td></tr></tbody></table><p>Rees, DC et al. <em>Nature Reviews Drug Discovery</em> 2004, 3, 660-67</p></div><div class="step" step="57" data-x="91200" data-y="0"><h1 id="id15">Fragment based drug discovery</h1><h2 id="at-high-concentrations-multiple-fragments-can-bind-to-a-protein">At high concentrations, multiple fragments can bind to a protein</h2><p>The binding of 3 fragments to p38a kinase.</p><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/fragment_p38_4ehv.png" alt="" width="40%" height=""></img>PDB: 4EHV</td><td><img src="images/fragment_4ehv.png" alt="" width="60%" height=""></img>PDB: 0SJ</td></tr></tbody></table><p>Over B et al. <em>Nat Chem</em> 2013 Jan;5(1):21-8</p></div><div class="step" step="58" data-x="92800" data-y="0"><h1 id="available-free-energy-calculation-tools-focus-on-1-1-interactions">Available free energy calculation tools focus on 1:1 interactions!</h1><img src="images/colored_PL.png" alt="" width="40%" height=""></img><p>We will <em>extend available free energy tools, as well as our ITC analysis</em> with a framework for multiple ligand association.</p></div><div class="step" step="59" data-x="94400" data-y="0"><h1 id="id16">Binding of multiple ligands to human serum albumin</h1><img src="images/HSA_extrasites.png" alt="" width="55%" height=""></img>A summary of human serum albumin (HSA) crystal structures bound to small molecules.<p>Ghuman, J et al. <em>J Mol Biol</em> 2005, 353, 38&#x2013;52</p></div><div class="step" step="60" data-x="96000" data-y="0"><h1 id="we-will-use-the-binding-of-nsaids-to-hsa-as-a-model-system">We will use the binding of NSAIDs to HSA as a model system</h1><table cellpadding="0" cellspacing="0"><tbody><tr><td rowspan="2"><p>Human serum albumin is</p><blockquote><ul><li>Cheap (1g for $50)</li><li>Soluble</li><li>Binds many known drugs</li></ul></blockquote><p>We will use NSAIDs</p><blockquote><ul><li>Widely used over-the-counter drugs</li><li>Commercially available</li><li>Available as soluble salt forms (important for ITC)</li></ul></blockquote></td><td><img src="images/aspirin.png" alt="" width="50%" height=""></img></td></tr><tr><td><img src="images/ibuprofen.png" alt="" width="50%" height=""></img></td></tr></tbody></table></div><div class="step" step="61" data-x="97600" data-y="0"><h1 id="for-each-equilibrium-we-define-a-binding-constant">For each equilibrium, we define a binding constant</h1><p>The binding constant <strong>Kn</strong> is a function of a stoichiometric binding free energy <strong>gn</strong>.</p><img src="images/colored_stoichiometric_constant.png" alt="" width="400px" height=""></img></div><div class="step" step="62" data-x="99200" data-y="0"><h1 id="an-alchemical-ladder-between-stoichiometric-states">An alchemical ladder between stoichiometric states</h1><p>We can then calculate the binding cooperativity between different stoichiometric states by constructing alchemical transitions that add a ligand.</p><img src="images/latex_images/equil_ladder.png" alt="" width="600px" height=""></img><p>There will be <strong>n+1</strong> non-alchemical states, from 0, to <strong>n</strong> ligands bound.</p></div><div class="step" step="63" data-x="100800" data-y="0"><h1 id="simulate-itc-experiments-from-calculated-free-energy-and-enthalpy">Simulate ITC experiments from calculated free energy and enthalpy</h1><ul><li>We obtain free energy <strong>g_n</strong> from alchemical free energy calculations, as well as the enthalpy (<strong>h_n</strong>)</li><li>We can use this data to simulate an ITC experiment</li><li>To do so, we simply calculate the heat at a given protein and ligand concentration for a given cell volume.</li></ul><img src="images/colored_qn_itc.png" alt="" width="400px" height=""></img></div><div class="step" step="64" data-x="102400" data-y="0"><h1 id="perform-itc-experiments-to-validate">Perform ITC experiments to validate</h1><p>After simulating ITC experiments, we will perform them to see if our computational predictions are correct.</p><p>To do so, we will extend our existing library with models that can fit multiple binding constants.</p><img src="images/github.png" alt="" width="30%" height=""></img></div><div class="step" step="65" data-x="104000" data-y="0"><h1 id="develop-a-framework-for-alchemical-free-energy-calculations-to-describe-weak-association-and-cooperative-ligand-binding">Develop a framework for alchemical free energy calculations to describe weak association and cooperative ligand binding.</h1><h2 id="aim-3">Aim 3.</h2><h3 id="subaim-3-1-extend-alchemical-free-energy-calculations-to-simulate-multiple-ligand-binding">Subaim 3.1: Extend alchemical free energy calculations to simulate multiple ligand binding.</h3><p>Current frameworks are focussed on single ligand (1:1) association to proteins</p><h3 id="subaim-3-2-validate-computational-predictions-by-applying-bayesian-model-selection-on-itc-experiments-of-hsa-and-a-series-of-nsaids">Subaim 3.2: Validate computational predictions by applying Bayesian model selection on ITC  experiments of HSA and a series of NSAIDs.</h3><p>We will expand the Bayesian ITC framework (Aim 1) to incorporate multiple ligand binding.</p></div><div class="step" step="66" data-x="105600" data-y="0"><h1 id="conclusion">Conclusion</h1><p>We hope to have addressed each of these issuess adequately, in order to improve the utility of alchemical free energy calculations.</p><img src="images/alchem_aims_red.png" alt="" width="95%" height=""></img></div><div class="step" step="67" data-x="107200" data-y="0"><h1 id="thanks-for-your-attention">Thanks for your attention!</h1></div><div class="step" step="68" data-x="108800" data-y="0"><h1 id="id17">It is all about the binding affinity</h1><p>A strong binder maximizes the ratio of complex concentration (<strong>[PL]</strong>) over free protein (<strong>[P]</strong>) and ligand (<strong>[L]</strong>).</p><p>This is known as the association constant (<strong>Ka</strong>).</p><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/colored_PL.png" alt="" width="300px" height=""></img></td></tr><tr><td><img src="images/colored_Ka_Kd.png" alt="" width="600px" height=""></img></td></tr></tbody></table></div><div class="step" step="69" data-x="110400" data-y="0"><h1 id="id18">It is all about the binding affinity</h1><p>A strong binder minimizes the ratio of free protein (<strong>[P]</strong>) and ligand (<strong>[L]</strong>) over complex concentration (<strong>[PL]</strong>).</p><p>This is known as the dissociation constant (<strong>Kd</strong>), often used synonymously with the binding affinity.</p><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/colored_PL.png" alt="" width="300px" height=""></img></td></tr><tr><td><img src="images/colored_Kd_Ka.png" alt="" width="600px" height=""></img></td></tr></tbody></table></div><div class="step" step="70" id="rocklin" data-x="112000" data-y="0"><h1 id="rocklin-charge-correction-model">Rocklin charge correction model</h1><img src="images/rocklinpbsa.png" alt="" width="400px" height=""></img><p>Poisson Boltzman calculations between a reference state (ligand in constant electric medium),
and the real state (ligand in solvent cavity).</p></div><div class="step" step="71" id="reif" data-x="113600" data-y="0"><h1 id="reif-oostenbrink">Reif-Oostenbrink</h1><p>Calculate the corrections in a thermodynamic cycle</p><img src="images/reif.png" alt="" width="60%" height=""></img></div><div class="step" step="72" data-x="115200" data-y="0"><h1 id="lin-model">Lin model</h1><img src="images/linmodel.png" alt="" width="300px" height=""></img></div><div class="step" step="73" id="weak" data-x="116800" data-y="0"><h1 id="weak-binding-of-fragments">Weak binding of fragments</h1><h2 id="consequences-of-the-strong-binding-approximation">Consequences of the strong binding approximation</h2><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/gilson.png" alt="" width="400px" height=""></img></td><td><img src="images/squarewell.png" alt="" width="300px" height=""></img></td></tr><tr><td><img src="images/strong_binding.png" alt="" width="400px" height=""></img></td><td></td></tr></tbody></table></div><div class="step" step="74" id="alchem" data-x="118400" data-y="0"><h1 id="id19">Alchemical free energy calculations</h1><h2 id="why">Why?</h2><p>They allow efficient sampling of the relevant states of protein-ligand complexes.</p><img src="images/colored_PL.png" alt="" width="30%" height=""></img><p>All you really need to sample are the <em>end states</em>!</p><p>www.alchemistry.org</p></div><div class="step" step="75" id="alchem-intermediates" data-x="120000" data-y="0"><h1 id="id20">Alchemical free energy calculations</h1><h2 id="alchemical-methods-allow-for-phase-space-overlap">Alchemical methods allow for phase space overlap</h2><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/normal_states.png" alt="" width="90%" height=""></img></td><td><img src="images/alchem_states.png" alt="" width="90%" height=""></img></td></tr><tr><td colspan="2"><img src="images/colored_zwanzig.png" alt="" width="60%" height=""></img></td></tr></tbody></table><p>Wu, D and Kofke, DA <em>J Chem Phys</em> 123: 054103 (2005).</p><p>Zwanzig, RW, <em>J Chem Phys</em> 22, 1420 (1954)</p><div class="notes"><p>You can interpret the equation as follows. We sample from state A, but use this to sample state B.
To unbias the samples, we remove a factor of exp(-beta U_A), and reweight by adding a factor of exp(-beta U_B).
If you sample A, the states might correspond to mostly high energy states in b, where the exponent of -U_B is very small,
meaning little contribution to the free energy. Therefore, your estimate converges very slowly.</p></div></div><div class="step" step="76" id="ewald" data-x="121600" data-y="0"><h1 id="ewald-summation-as-a-long-range-electrostatics-approxmation">Ewald summation as a long range electrostatics approxmation</h1><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/pbc_ewald.png" alt="" width="300px" height=""></img>An infinitely periodic system as a lattice.</td><td><img src="images/ewald.png" alt="" width="300px" height=""></img>Charges are additionally described with distributions.</td></tr></tbody></table><div class="notes"><p>real space part: Ureal = 1/2 sum i=1 to N sum j=1 to N sum |n| =0 to infinity (qi qj)/(4pi eps0)  * erfc(alph |rij + n|)/ |rij +n|</p><p>reciprocal space part: U_reci = 1/2 sum k ne 0 sum i=1 to N sum j=1 to N (qi qj)/(4pi eps0)  4 pi^2 /k^2 exp (- k^2/4alph^2) cos(k*rij)</p><p>subtract self term:  - alpha/ sqr(pi) sum k=1 to n  q^2_k / (4pi eps0)</p><p>correction if not tin foil: (2pi)/(3L^3) sum =1 to N (qi/(4pi eps0) ri )^2</p></div></div><div class="step" step="77" data-x="123200" data-y="0"><h1 id="ewald-summation">Ewald summation</h1><h2 id="id21">Neutralizing the system charge</h2><p>There is an effective system neutralizing charge, called jellium/gellium.</p><p>This system wide charge density &#x3C1; depends on the box size, L.</p><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/pbc_ewald.png" alt="" width="300px" height=""></img>An infinitely periodic system as a lattice.</td><td><img src="images/colored_gellium.png" alt="" width="400px" height=""></img>The charge density in the system is a function of the box size.</td></tr></tbody></table><p>Here, <strong>k</strong> stands for the different boxes in the lattice, and <strong>i</strong> indicates individual point charges <strong>q_i</strong>, with their position vectors <strong>r&#x20D7;</strong>.</p></div><div class="step" step="78" id="parameters" data-x="124800" data-y="0"><h1 id="id22">Accurately quantify experimental uncertainty using Bayesian inference.</h1><h2 id="the-itc-model-structure">The ITC model structure</h2><img src="images/colored_parameters.png" alt="" width="" height=""></img><p>Thermodynamic parameters include</p><blockquote><ul><li>binding affinity, <strong>&#x394;G</strong></li><li>enthalpy of binding, <strong>&#x394;H</strong></li><li>mechanical heats offset, <strong>&#x394;H0</strong></li><li>concentration of syringe component, <strong>[Xs]</strong></li><li>concentration of cell component, <strong>[Mc]</strong></li><li>noise parameter, <strong>&#x3C3;</strong></li></ul></blockquote><p>We use prior distributions <strong>P(&#x3B8;)</strong> to propagate error estimates in concentrations, and previously obtained data.</p></div><div class="step" step="79" data-x="126400" data-y="0"><h1 id="id23">Protonation states may vary for kinase inhibitors</h1><h2 id="egfr-inhibitors-lapatinib-and-gefitinib">EGFR inhibitors lapatinib and gefitinib</h2><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/lapatinib.png" alt="" width="80%" height=""></img>Lapatinib</td><td><img src="images/gefitinib.png" alt="" width="80%" height=""></img>Gefitinib</td></tr></tbody></table><p>Many FDA approved kinase inhibitors have titratable moieties with pKas near 7.</p><p>(image source: www.chemicalize.org)</p><div class="notes"><p>These two drugs are EGFR/Her2 inhibitors, important in lung and breast cancers
(Non small cell lung cancer)</p></div></div><div class="step" step="80" data-x="128000" data-y="0"><h1 id="id24">Quantify the magnitude of protonation state effects on binding</h1><p>It is known for several well-studied systems that protonation states make a large difference.</p><img src="images/cz_hiv.jpg" alt="" width="50%" height=""></img><em>HIV protease inhibitors induce protonation state changes in active site aspartate residues.</em></div><div class="step" step="81" data-x="129600" data-y="0"><h1 id="id25">Protonation states are relevant to kinase inhibitors</h1><ul><li>Kinases are hugely important targets for anti cancer drugs.</li><li>Evidence exists that for the binding of imatinib to Abl kinase, pH dependent effects may contribute to the binding affinity, and preliminary data indicates that it is the same for <em>many other kinase inhibitors</em>.</li></ul><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/inhibitor-pKas.png" alt="" width="40%" height=""></img></td><td><img src="images/imatinib_image_curve.png" alt="" width="50%" height=""></img></td></tr></tbody></table><p>Szak&#xE1;cs Z, et al. <em>J Med Chem</em> 48, 249&#x2013;255 (2005)</p></div><div class="step" step="82" id="enrichment" data-x="131200" data-y="0"><h1 id="docking-can-provide-enrichment-in-top-10-scores">Docking can provide enrichment in top 10 scores</h1><img src="images/enrichment.gif" alt="" width="70%" height=""></img><p>Warren et al. <em>J Med Chem</em> 49 (20), pp 5912&#x2013;5931 (2006)</p></div><div class="step" step="83" id="postheats" data-x="132800" data-y="0"><h1 id="uncertainty-in-the-data">Uncertainty in the data</h1><p>Red dots &#x2022; indicate observed data, violins depict the posterior distribution of each injection.
The family of models that were sampled are shown as black curves.</p><table cellpadding="0" cellspacing="0"><tbody><tr><td><img src="images/postpredictive.png" alt="" width="70%" height=""></img></td></tr></tbody></table></div><div class="step" step="84" data-x="134400" data-y="0"><h1 id="id26">Protonation states may vary for kinase inhibitors</h1><h2 id="id27">Imatinib, a potent inhibitor of Abl kinase</h2><img src="images/imatinib_image_curve.png" alt="" width="50%" height=""></img><p>Szak&#xE1;cs, Z. et al. <em>J Med Chem</em> 2005, 48, 249&#x2013;255</p><div class="notes"><p>Do not forget to mention that the protonated form of these inhibitors is charged</p></div></div><div class="step" step="85" data-x="136000" data-y="0"><h1 id="id28">Protonation states may vary for kinase inhibitors</h1><h2 id="id29">Imatinib, a potent inhibitor of Abl kinase</h2><img src="images/imatinib_sites.png" alt="" width="50%" height=""></img></div><div class="step" step="86" data-x="137600" data-y="0"><h1 id="the-pka-tools-we-will-consider">The pKa tools we will consider</h1><ul><li><strong>MoKa</strong> generates pKa s based on atomistic descriptors, defined by the surrounding atoms. The descriptors are based on molecular interaction fields calculated using GRID for a library of 3D fragments, but can successfully be applied on 2D structures.</li><li>Schrodinger&#x2019;s <strong>Jaguar</strong> provides means of estimating pKa values using quantum mechanical methods.</li><li><strong>Epik</strong> uses Hammett Taft linear free energy approaches for predicting pKa values.</li></ul></div><div class="step" step="87" data-x="139200" data-y="0"><h1 id="the-stoichiometric-free-energy">The stoichiometric free energy</h1><h2 id="the-free-energy-is-reduced-to-just-receptor-ligand-interactions">The free energy is reduced to just receptor-ligand interactions</h2><p>The free energy (<strong>gn</strong>) is defined</p><img src="images/colored_gn_semigrand.png" alt="" width="700px" height=""></img><p>where <strong>un</strong> is a reduced potential energy, including just ligand-receptor interactions.</p><img src="images/colored_un_semigrand.png" alt="" width="700px" height=""></img></div><div class="step" step="88" data-x="140800" data-y="0"><h1 id="the-binding-constants-combined-into-a-single-polynomial">The binding constants combined into a single polynomial</h1><p>It can be shown when you define a polynomial of all binding constants <strong>Kn</strong></p><img src="images/colored_binding_poly.png" alt="" width="600px" height=""></img><p>the free energy can be defined as such</p><img src="images/colored_g_kt_lnq.png" alt="" width="300px" height=""></img><p><strong>Q[L]</strong> here is also referred to as the semi-grand canonical partition function.</p></div><div class="step" step="89" data-x="142400" data-y="0"><h1 id="perform-complimentary-itc-experiments-on-hsa">Perform complimentary ITC experiments on HSA</h1><p>From the semi-grand canonical ensemble methodology, we can fit the polynomial as a function of ligand concentration</p><img src="images/colored_binding_poly.png" alt="" width="600px" height=""></img><p>and use Bayesian inference to infer the value of the <strong>Kn</strong> coefficients.</p><p>Using Bayesian model selection, we may select for the optimum number of coefficients to fit.</p><div class="notes"><p>Reversible jump</p></div></div><div class="step" step="90" data-x="144000" data-y="0"><h1 id="bayesian-experimental-design">Bayesian experimental design</h1><ul><li>It might be hard to recapitulate the entire curve from a single ITC experiment</li><li>Higher order binding constants are expected to have large uncertainty</li><li>We can use Bayesian experimental design to suggest follow up experiments that increase our expectation</li></ul><div class="notes"><p>Especially if the site constants are very different in order of magnitude, we may need different experimental conditions</p><p>expected value of the log likelihood function, with respect to the conditional distribution of Z  given D under the current estimate of the parameters theta</p></div></div><div class="step" step="91" data-x="145600" data-y="0"><p>This slide is intentionally left blank.</p></div></div><div id="hovercraft-help"><table><tr><th>Space</th><td>Forward</td></tr><tr><th>Left, Down, Page Down</th><td>Next slide</td></tr><tr><th>Right, Up, Page Up</th><td>Previous slide</td></tr><tr><th>P</th><td>Open presenter console</td></tr><tr><th>H</th><td>Toggle this help</td></tr></table></div><script type="text/javascript" src="js/impress.js"></script><script type="text/javascript" src="js/impressConsole.js"></script><script type="text/javascript" src="js/hovercraft.js"></script></body></html>